Glucose lowering strategies with insulin by Taylor, M. Joan et al.
CURRENT TOPICS
Glucose lowering strategies with insulin 
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Abstract 
People with type 1 diabetes must use insulin and a large 
fraction of those with type 2 condition also do so. Many 
therefore struggle with the unpredictable balancing of in-
sulin dose with calorie intake and utility. A healthy pancreas 
makes meticulous adjustment on a continuous basis that 
present therapeutic insulin administration cannot match. 
However, much progress has been made to make it simpler 
to inject both background and fast-acting boost insulins with 
a view to better mimicking normal pancreatic output. The 
present fast insulins are reviewed with accent on the primary 
amino acid structures of the biosynthetic types that diffuse 
more quickly than regular insulin that associates in hexam-
ers. This makes boost doses kinetically and clinically more   
effective, allowing people to inject better estimated boost 
and corrective doses. Formulation advances are discussed for 
their present and potential contributions. The newer slow-
acting insulins are also described and compared, their advan-
tage also being kinetic with a lower likelihood of inducing 
overnight hypoglycaemia when used optimally. Finally, the 
appreciation of the advantages of alternative routes of ad-
ministration such as oral and peritoneal are included in this 
review because of the possibility of altering the hepatic to 
peripheral ratio, the reasons for which are more effective but 
less obesogenic insulin activity. The logistics of oral insulin 
are summarised in terms of the risks to the insulin structure, 
the facilitation of paracellular uptake at the apical surface 
and the paradoxically advantageous hepatic first pass. Other 
non-invasive routes are also included in the review. 
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Introduction 
Many patients with type 2 diabetes (T2D), all patients with type 1 
diabetes (T1D) and eventually almost all those with latent autoim-
mune diabetes of adulthood (LADA) need insulin, the latter − as 
with conventional T1D − to prevent ketoacidosis. For all insulin 
users, the aim should be to match insulin delivery to the pattern 
found physiologically in healthy counterparts, in order to keep the 
blood glucose within the target range for most of the time. For 
T1D, success is often only partial and so HbA1c values are com-
monly higher than target. This is true even for children for whom 
preventive measures for complications are so important.1–3 The rea-
son is that the risk of hypoglycaemia is commonly perceived to out-
weigh the risk of long-term complications in the day-to-day 
management of many users, perhaps particularly for children. This 
may relate to concomitant glucagon and/or glycogenolysis failures 
or glucagon resistance.4 It is the case, therefore, that a significant 
fraction of the diabetic patient population needs improvements in 
the methods used to deliver insulin in order to improve safety and 
efficacy. Here, we chart progress in the design of approaches from 
the conventional to the innovative and futuristic. We will review 
various strategies including formulations to deliver, stabilise and 
protect the insulin molecule, improve comfort, convenience and 
compliance with the ultimate aim of optimising glycaemic control.5   
  
Open and closed loop 
Open loop and tight control 
Since the demonstration that tight control of blood glucose (BG) is 
beneficial for the prevention of diabetes complications, multi-dose 
injection (MDI) with basal and bolus (prandial and corrective) insulin 
accompanied by frequent BG testing has become the standard for 
T1D and not uncommon for T2D. Structured education pro-
grammes such as DAFNE and DESMOND have enabled people to 
take advantage of these approaches. The tools for the job include 
the increasingly improved BG meters, flash and continuous glucose 
monitoring systems (CGMS), smart phones for capturing, logging 
and manipulating data, internet guidance, improved injection       
devices and new insulins. 
Open loop treatment of diabetes is the term used when the 
judgement of quantity and timing of insulin is left to the users, car-
ers and/or prescribers.6 This may be as unsophisticated as to impose 
a relatively constant daily macronutrient regimen (content and tim-
ing) while prescribing  a fixed, matched quantity of insulin. The ad-
justment is usually made by healthcare providers on behalf of the 
individual in an attempt to keep BG within reasonable limits. This 
is no longer regarded as a suitable approach for the majority of 
people with T1D, for whom a more intensive MDI or insulin pump 
regimen is recommended which is sufficiently flexible to achieve 
tight glucose control despite variable amounts and timing of food, 
physical activity etc, thus placing the decision with the user rather 
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than the prescriber. Intensive control therefore requires the user to 
measure the BG fairly frequently and to calculate and administer 
bolus doses before food and as corrections. This method clearly       
relies on education and accurate BG information, often entering the 
latter on bolus advisor meters or phone apps that are available to 
help cope with the complexity and continual nature of the demands. 
The advent of flash and CGMS, that measure tissue fluid glucose 
rather than BG, gives information that is collected many times per 
hour, albeit with a potentially significant time lag in comparison with 
BG. Achieving  tight control in order to reduce HbA1c to the T1D 
optimum 48 mmol/mol (6.5%) is challenging because, not only is 
the BG a moving target, but a distorted sympathetic neuronal con-
trol of the glucagon-based counter-regulatory system may compli-
cate the effects of imposition of harsh antihyperglycaemic doses/ 
pump dose rates. Resulting hypos are common,7 estimated at 
CGMS-measured 2.1 events per 24 hours that often go unnoticed 
even in hypo-aware people. This mitigates against safe glucose con-
trol despite the likely lower HbA1c results and is especially true in 
people with hypoglycaemia unawareness. This has led to the con-
cept of glucose targets being set for ‘time in range’ rather than 
HbA1c.   
 
Development of injectable insulins for intensive control 
regimens 
A variety of innovative fast- and slow-acting insulins are now avail-
able, including the ultra-long-acting degludec and fast-acting           
insulins such as glulisine and fast aspart. Their purpose is to make 
tight control achievable by providing the tools for imposing sus-
tained background control and tailored fast-acting doses around 
mealtimes to prevent post-meal hyperglycaemia without delayed 
hypoglycaemia. Over the last decades, specific insulins have been 
marketed that claim to have advantages when used in MDI regi-
mens.   
The structure, design strategies and formulation are comprehen-
sively reviewed by various authors4,8,9 but briefly, have mainly             
involved the biosynthetic alteration of the amino acid content,         
sequence and/or conjugation, resulting in changes in charge,          
hydrogen bonding and hydrophobicity. These modifications create 
the required pharmacokinetics either by solubility, competitive bind-
ing or changes in quaternary association, although modified insulins 
are generally inherently less resistant to physical destabilisation than 
the native molecule that normally groups in dimers and hexamers 
in concentrated solution (Figures 1 and 2).10 
Formulatory changes in the solvent medium for  insulins are ad-
ditional common approaches,11,12 with polyethylene glycol (PEG), 
glycerol and ethanol having been tried for their effects on electro-
static interactions in the highly polar insulin molecule. Chelating 
agents, antioxidant sugars, surfactants and amino acids such as        
lysine, arginine and glycine have also featured in developmental 
work, often to create the monomeric form. Linjeta (Viaject) was for-
mulated with EDTA and citric acid to chelate zinc, for example, but 
has not been pursued. Two agents have been incorporated with        
aspart (Novorapid®, Novo Nordisk), a monomeric insulin that is given 
as a preprandial bolus and is commonly used in insulin pumps13,14 
because it may be cleared from the subcutaneous tissue quickly 
enough to transmit pump rate changes to appropriate modification 
of BG adjustment. Loss from skin to plasma is a more blunted pro-
cess with soluble insulins that persist in hexamers, because the dif-
fusion coefficient is much lower. Fiasp® (Novo Nordisk), like the 
normal version of aspart, contains glycerol, metacresol, phenol, zinc 
and pH adjustment by phosphate, hydroxide and hydrochloric acid. 
Figure 1. The primary structure of human insulin
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Figure 2. The biosynthetic short-acting insulins in current 
use: lispro, lysine and proline reversed at B28 and 
29 (top); glulisine, asparagine at B3 and glutamic 
acid at B29 (middle); aspart, aspartic acid at B28 
(bottom)
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However, it achieves an even more prompt onset of action and 
physiological profile by the addition of niacinamide (nicotinamide, 
niacin, vitamin B3) as an absorption enhancer that works not only 
as a localised vasodilator, but by increasing the fast diffusing 
monomer fraction by about 35%.15 L-arginine is an additional 
agent working as a refolding protector and thus a stabiliser against 
aggregation. In this context, aggregation means an unwanted 
grouping in unspecified numbers of large molecules, usually pep-
tides and proteins. It is different either from association into qua-
ternary structuring such as hexamers or amorphous precipitation 
such as occurs with excess zinc or at the isoelectric zwitterionic pH 
point (pI), which can each preserve activity, as does crystallisation, 
even if some reversible unfolding happens. In aggregation, how-
ever, the normal tertiary and quaternary structures are lost because 
it involves irreversible unfolding. Correct folding is accomplished in 
the beta cell’s endoplasmic reticulum and is normally vital for activity 
whether the insulin is endogenous or biotechnically synthesised. 
Unfolding is therefore a serious degradative change that may facil-
itate further permanent transformation, often involving amyloid       
fibrous structures that are inactive, potentially antigenic and can 
accumulate at injection sites. An aggregation protector is therefore 
an important formulation success. In the past, soluble Hoe21PH      
insulin for pump use was stabilised against aggregation by the 
poloxamer micellisation agent Genapol, in line with surfactant 
strategies for proteins stabilised in general.16,17 In the case of Fiasp®, 
the combined changes to the previous aspart formulation halve the 
time of appearance in plasma with 74% greater insulin action 
within the first 30 min, the clear aim being better postprandial con-
trol.14,18   
By contrast, detemir and degludec were synthesised as soluble, 
long-acting products both involving the covalent addition of poly-
meric lipophilic side chains.9,19 These alter the kinetics to produce 
low level basal dosage with a flattened plasma profile; this was an 
improvement on what could be achieved with suspension products 
like isophane (NPH) insulins and with insulin zinc suspension (IZS). 
The clinical value with these newer products in MDI regimens was 
the reduction in overnight hypoglycaemic events. Detemir has a 
myristic (C14) acid substitution at a terminal B29 lysine (no threo-
nine), and its slow action is attributable to hydrophobic self-associ-
ation in tissues and also to binding of the acyl chain to fatty acid 
binding sites on serum albumin.6,20 A further flattened profile is      
associated with degludec (t1/2 ~25 hours, duration >40 hours) and 
is enabled because, despite its superficial similarity to detemir, its 
des-30-structure (again no threonine) forms very long unique hex-
americ sequences stabilised by zinc, phenol and hydrophobic con-
tact between covalently attached hexadecanoic (C16) diacid chains 
linked at B29 with glutamic acid.9,19 These lipophilic agents there-
fore differ from an alternative soluble long-acting insulin, glargine, 
which has a replacement of glycine for asparagine at position A21 
and addition of two arginine molecules at positions B29–30. This 
alters the pI such that precipitation occurs at pH 7.4 instead of 5.4 
as with native insulin (Figure 3), thus creating a subcutaneous 
depot.   
A variety of other new kinetic approaches included a liver-       
specific analogue that was an interesting departure. Peglispro 
(LY2605541) was a developmental effort to slow the release but 
also to raise the ratio of hepatic to peripheral insulin, changing the 
ratio of hepatic glycogenolysis to peripheral glucose disposal and 
thus to suppress the weight gain associated with insulin medica-
tion. Other strategies such as oral insulin have a similar aim. The 
5.8 kDa insulin lispro monomer had a 20 kDa linear PEG moiety 
covalently bound to the B28 lysine (not B29 as in native insulin), 
and promoting the binding of three water molecules thus giving a 
hydrodynamic radius equivalent to a globular molecule of about 
78 kDa. This slowed the renal excretion as well as the absorption 
from the subcutaneous administration site. Peglispro binding to the 
insulin receptor is much reduced and thus the effective molar dose 
is greater. Madsbad21 reviewed the evidence for the hepatic speci-
ficity and Hirose22 pointed out the additional protective effect of 
the pegylation towards proteolytic enzymes. By 2015, however, this 
compound had failed its clinical assessment because of unaccept-
able lipid values and liver function tests.23   
 
Closed loop: the automation of tight control 
The closed loop system is the long-term aim of diabetes control 
using exogenous insulin because it takes decision-making by the 
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Figure 3. The biosynthetic soluble long-acting insulins in 
current use: glargine, terminal A chain asparagine 
to glycine and terminal B chain lysine and threonine 
to arginines (top); detemir, acyl group at B29 lysine 
(middle); degludec, hexadecanoic (C16) diacid 
chains linked at B29 lysine with a glutamic acid 
linker (bottom). Bottom left shows the insulin 
hexamer and its ability to form strings in degludec  
insulin
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user out of the system24,25 and, in the optimum embodiment, op-
erates by several components including a frequent coupling with 
real-time sensing to correct BG in small steps, fast response for each 
corrective move and prompt catabolic mechanisms so that excess 
insulin is removed (Figure 4).   
These points all emulate the physiological process and, to com-
plete the best possible outcome, the insulin output should ideally 
be oscillatory with a frequency of minutes (ie, within the BG            
adjustment cycles).26 Oscillatory release is thought to minimise the 
downregulation of tissue receptors and oppose resistance develop-
ing which is a risk even in T1D.27 Closed loop systems working to 
these principles should avoid the danger of hypos yet be able to 
respond in real time to postprandial and counter-regulatory peaks, 
keeping BG within normal tolerances 100% of the time.   
Currently there are three approaches to closed loop systems: 
biological (pancreas or islet transplants), electronic (artificial pan-
creas) and chemical (including smart insulin formulations), of which 
only the first two are in human development and use, and have 
been reviewed elsewhere.  
The remainder of this article is the formulation of insulins that 
interact with tissue/BG such as to regulate insulin output. 
  
Routes for insulin delivery in closed loop systems  
Injectable and implantable 
All people with T1D and about 25% of those with T2D are pre-
scribed recipients of formulations intended mainly for subcuta-
neous injection. While this route is not the fastest route for 
absorption, it has the advantage of being an easily-learned tech-
nique for self-administration. Its exploitation therapeutically has 
been the norm, especially as it was safe for the longer acting 
suspension formulations that have been used for many years. 
However, some people with diabetes are needle phobic, develop 
injection site lipohypertrophy or localised allergy or bruise         
because of concomitant anticoagulant therapy. As a general 
consequence, efforts have been made to exploit alternative par-
enteral delivery paradigms such as microneedles, pumps, patch 
pumps and patches, as well as other routes of administration 
that are less invasive. Other considerations are important, so that 
the peritoneal route circumvents the delays due to the dense, 
fatty subcutaneous skin layer and can be built into viscerally ad-
ministered insulin from devices, possibly with a similarly placed 
sensor.25,28–32 This may solve the potential iatrogenic problem of 
the non-physiological effects of distorting the peripheral and 
hepatic concentration ratio of released insulin, as discussed also 
below. In a different context, Rhea et al33 report access to the 
CNS mainly by intrathecal, cerebral, ventricular but also nasal 
and ocular routes, for idiopathic CNS insulin resistance that is 
inadequately treated by peripheral administration. 
 
Oral  
Alternatives to parenteral delivery feature high in diabetes phar-
maceutical research.34 The oral route has been a long-term goal 
for insulin delivery, not only for convenience and compliance but 
because the mesenteric to portal drainage implies a potentially 
normal ratio of hepatic to peripheral insulin, fostering normal 
liver regulation of hyperglycaemia and differing markedly from 
parenteral delivery.35,36 However, the harsh environment of pro-
teolytic digestive enzymes, food interaction and the obstacles to 
the absorption of large molecules has meant that development 
has been slow, waiting for tactics to overcome the problems. 
Protective strategies include chitosan, an aminopolysaccharide 
gel derived from crustacean shell.37,38 
Access to gut vasculature via the apical aspect of the gut      
epithelium is an equal challenge. The transport of large polar 
molecules depends largely on the paracellular route, implying 
the traversing of a complex mixed environment gap between 
cells that is also size limited. Information about the paracellular 
gap size is variable. Anderson comments that the biology and 
pharmaceutics approaches differ, and typically drug delivery 
studies use a series of labelled tracers that may or may not be 
charged, while transcytosis may be ignored in the assessment.39 
Chitosan and its quaternised derivatives such as trimethylchi-
tosan have the ability to influence permeation by accessing 
claudin and actin structures.37,38,40–43 However, the balance of 
alkyl chain length and charge on the water solubility permeation 
effectiveness and tight junction molecular recovery is critical, as 
discussed by Benediktsdóttir et al.44 Maher et al categorise both 
paracellular and transcellular mechanisms, highlighting sucrose 
laurate, a surfactant-like material, as well as the phosphatase in-
hibitor PIP 640 and some ionic liquids such as choline geronate 
(CAGE).45 These may influence tight junctions to increase gut 
uptake of insulin, as may the formulation as nanoparticles.45 
Biologically, it seems that two paracellular routes may co-exist, 
Figure 4. Closed loop control: implies the automation of 
insulin dosage, meticulous and frequent 
adjustment replacing the necessity of the user 
decision points A and B. 
A 
output needs 
raising to cope 




Insulin output should  
ideally be reducing (as 
with a pump or if  
automated by closed 
loop) but if insulin is  
injected as bolus doses, 
the only option is to eat 
to prevent hypoglycaemia
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namely a high capacity one with steep size dependence, a cut-off 
of 4 Å and a larger gap that may occur in intact tight junctions 
under the influence of inflammatory cytokines. A gap size of 2–5 
Å is thus often quoted but, depending on tissue, where normal 
transport can admit molecules of 200 Da such as mannitol (3.5 Å) 
but not usually the fructal inulin (molecular weight variable but pos-
sibly 3–5 kDa and about 11 Å, thus approaching insulin monomer 
size). However, Taverner holds that ileal tight junctions can exist in 
open and shut form, as a function of the phosphorylation of light 
chain myosin and its regulatory kinase system that maintains a cir-
cumferential tension. Several efforts have been made to set the de-
fault to open the junctions for insulin transport through the apical 
surface using kinase system blockers that have been shown to per-
mit transport of labelled dextran of 70 kDa.46 In another approach, 
chitosans have been used not only for their protective effect but 
because they can open tight junctions in a transient and reversible 
manner by a disruption of claudin-4, a tight junction protein.43   
 
Other non-invasive routes 
The use of other routes involving transport across mucous mem-
branes is reviewed by Easa et al.35 Briefly, inhaled insulin has       
undergone a revival as Afrezza since the abortive attempt with 
the unwieldy Exubera, because the theory is well-developed, as 
reviewed by Lin et al,47 and the practicalities have been im-
proved. Transdermal delivery can also include microneedles and, 
for completeness, it should be mentioned here that iontophore-
sis systems have been widely studied and sometimes combined 
with microneedles. Buccal and nasal routes are conceivable, so 
that micelle-associated insulin in Generex’s Ora-lyn has been re-
ported as beginning trials in 2019, but Aquestive’s bioadhesive 
film associated with glycan and insulin aspart-bearing gold 
nanoparticles (1–2 nm) has failed because, although the particles 
were renally eliminated and despite apparent absorption 
through buccal tight junctions, the product demonstrated im-
practically low bioavailability.35 Nevertheless, buccal formulations 
– as well as providing access paracellularly – could be developed 
to optimise as least basal dose.48–50 Rectal and vaginal routes 
seem impractical and neither finds many recent citations except 
in reviews51,52 or as a rectal instillation (for anti-inflammatory 
treatment of colitis rather than for its antihyperglycaemic prop-
erties).53 The ophthalmic route may be effective, as shown in      
accidental systemic toxicity after an insulin eye mishap,54 but pre-
dictability is an issue due to nasolacrimal loss and other dose im-
practicalities. The reality is also that administration of insulin by 
these alternative routes – or, indeed, by parenteral routes other 
than peritoneal – is unable to emulate the physiological hepatic 
to peripheral insulin ratio, except for the potential of oral delivery 
(see above). Ironically, in drug delivery generally, many alternative 
routes are developed to avoid hepatic first pass effects. However, 
for insulin, first pass would enable the advantageous liver effects 
that are suppressed with non-oral delivery. The major effect of 
hepatic targeting is to curb glycogenolysis and also gluconeo-
genesis compared with normal, and so glucose peaks are harder 
to control unless the liver is targeted. Hepatocentric activity 
would be an asset because a further factor is that glucagon is 
also often poorly regulated in diabetes so that hyperglycaemic 
peaks postprandially are potentially exaggerated for that reason 
also. Finally, the peripheral effects of excess insulin on adipose 
tissue are obesogenic, which affects treatment compliance.52   
 
Conclusions 
The quest for much more physiological insulin delivery has been 
ongoing for many decades, ever since the realisation that crudely 
dissolved insulin was life-saving but not as a long-term sustainable 
treatment. It is true that great strides have been made such that 
diabetic people can now be in possession of the information about 
their glucose status on a minute-by-minute basis. They have the 
tools to plan background dosage with bolus doses to cover meals 
and aim for low HbA1c values yet avoid repeated hypoglycaemic 
crises. Eating and exercising variably are possible, thanks to educa-
tion programmes to take advantage of these strategies. The advent 
of smart phone apps has made this easier, yet still BG and HbA1c 
levels are too high. The problem is that the target moves, but the 
delivery of insulin cannot keep pace with the variable need. On the 
whole, people avoid hypoglycaemia at the expense of hypergly-
caemia. A closed system is needed. The perception of a slow pace 








• The subcutaneous route for daily divided doses or 
pumped insulin comprises current therapy for most 
people who use insulin 
• The delays in attempting to alter the dose and dose 
rates in multi-dose and pump systems, respectively, are 
due to the rate-determining step of the transfer of the 
large hydrophilic molecule from fatty tissue into 
capillaries 
• A second non-physiological step when normal 
physiological delivery is replaced by subcutaneous 
delivery is the low concentration gradient in the liver 
leading to a reduced hepatic to peripheral ratio. New 
formulations may increase hepatic targeting even for 
subcutaneously delivered drug, but the oral and 
peritoneal routes may also accomplish this 
• Closed loop delivery will eventually improve manual 
programmes for ‘tight control’ programmes, and the 
subcutaneous delays in both the insulin delivery and 
the glucose sensing are slowly becoming less of an 
obstacle to safe automatic upwards adjustment of 
insulin delivery for preventing postprandial glucose 
surges 
• Much has improved in insulin management of 
diabetes, but new insulins, new routes and automated 
systems should achieve better control and improved 
outcomes 
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have become skilled enough to be able to combine pump delivery 
and sensor to create fairly adventurous and sophisticated artificial 
pancreases, as described on the Nightscout webpage.55 The phys-
iological delays that limit the kinetics of skin sensors and delivery 
systems remain a barrier to development of this type, however, 
whatever the source. Since algorithm development cannot detect 
what has not yet happened as a meal is consumed, subcutaneous 
systems must undergo a change or replacement in the quest. Other 
systems such as oral, transdermal and pulmonary may ultimately 
prove to be superior to subcutaneous basal insulins. 
 
This is an accompanying article of a talk given at the Royal Society 
of Medicine in London on 13 June 2019 on “New technologies in 
diabetes”.  
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